Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Adenocarcinoma × Cisplatin × Clear all

Phase

Phase 2 13 Phase 3 4 Phase 1 4 Phase 1/2 2 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 10 Esophageal Neoplasms 7 Nasopharyngeal Carcinoma 6 Lung Neoplasms 6 Esophageal Squamous Cell Carcinoma 6 Squamous Cell Carcinoma of Head and Neck 5 Uterine Cervical Neoplasms 4 Pancreatic Neoplasms 4 Head and Neck Neoplasms 4 Cholangiocarcinoma 4 Biliary Tract Neoplasms 4 Urinary Bladder Neoplasms 3 Stomach Neoplasms 3 Neoplasm Metastasis 3 Mesothelioma 3 Gallbladder Neoplasms 3 Carcinoma 3 Breast Neoplasms 3 Osteosarcoma 2 Oropharyngeal Neoplasms 2 Endometrial Neoplasms 2 Carcinoma, Transitional Cell 2 Bile Duct Neoplasms 2 Adenocarcinoma Of Esophagus 2 Triple Negative Breast Neoplasms 1 Thymoma 1 Thymic epithelial tumor 1 Sarcoma 1 Renal Pelvis and Ureter Urothelial Carcinoma 1 Peritoneal Neoplasms 1

Interventions

Oxaliplatin 2 Fluorouracil 2 rubitecan 1 nimotuzumab 1 halofantrine 1 gallium 68 PSMA-11 1 camrelizumab 1 apatinib 1 S 1 (combination) 1 Radiotherapy 1 Radiosurgery 1 Radiation 1 Photochemotherapy 1 Nadroparin 1 Heparin, Low-Molecular-Weight 1 Gastrectomy 1 Esophagectomy 1 Docetaxel 1 Cisplatin 1 Chemoradiotherapy 1 Capecitabine 1 CP protocol 1 Brachytherapy 1 Atrasentan 1 Androgen Antagonists 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01249352 2025-03-31

NICE

Eurofarma Laboratorios S.A.

Phase 2/3 Completed

Gastrointestinal

Adenocarcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡